Ignite Creation Date:
2024-05-06 @ 6:19 PM
Last Modification Date:
2024-10-26 @ 2:46 PM
Study NCT ID:
NCT05623592
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-10
First Post:
2022-11-08
Brief Title:
Methotrexate as Remission Maintenance Therapy After Remission-Induction With Tocilizumab and Glucocorticoids in Giant Cell Arteritis
Sponsor:
University of Bonn
Organization:
University of Bonn
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Parallel Group Study to Evaluate the Efficacy of Methotrexate as Remission Maintenance Therapy After Remission-Induction Therapy With Tocilizumab and Glucocorticoids in Subjects With Giant Cell Arteritis
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MTXinGCA
Brief Summary:
The standard treatment for Giant Cell arteritis GCA is GlucocorticoidsGC even if GC-related adverse events are commonly occuring Therefore other practises for reducing relapses and cumulative GC-doses are needed Currently the Interleukin-6-inhibitor tocilizumab is used in combination with GC to achieve higher remission rates and lower cumulative GC-doses The use of tocilizumab also has some disadvantages One is the increased susceptibility to infections On top of that a long-term follow-up of the phase II study by Villiger et al showed a 55 relapse-rate after discontinuation of intravenous tocilizumab after a median of five months
Studies have also shown that methotrexateMTX in combination with GC was able to prevent relapses and reduce cumulative GC doses
The aim of the study is to evaluate whether MTX is superior to placebo to prevent relapses in subjects with GCA after Remission-Induction Therapy with Glucocorticoids and Tocilizumab Our hypothesis is that Methotrexate can maintain remission once stable remission has been induced by GC and Tocilizumab and will prevent the occurrence of relapses
Studies have also shown that methotrexateMTX in combination with GC was able to prevent relapses and reduce cumulative GC doses
The aim of the study is to evaluate whether MTX is superior to placebo to prevent relapses in subjects with GCA after Remission-Induction Therapy with Glucocorticoids and Tocilizumab Our hypothesis is that Methotrexate can maintain remission once stable remission has been induced by GC and Tocilizumab and will prevent the occurrence of relapses
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| DRKS-ID DRKS00030571 | OTHER | German Clinical Trials Register | None |
| EU-CT No 2022-501058-12-00 | OTHER | None | None |